# Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer

> **NCT03698370** · PHASE2 · COMPLETED · sponsor: **Andrei Iagaru** · enrollment: 27 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- PSA Progression
- Recurrent Prostate Carcinoma

## Interventions

- **DRUG:** Gallium Ga 68 DOTA-NeoBOMB1
- **DEVICE:** Gallium Ga 68 PSMA-R2

## Key facts

- **NCT ID:** NCT03698370
- **Lead sponsor:** Andrei Iagaru
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-15
- **Primary completion:** 2022-02-11
- **Final completion:** 2022-02-11
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03698370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03698370, "Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03698370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*